1. Home
  2. CTSO

as of 11-20-2026 12:45pm EST

$4.52
$0.74
-14.07%
Stocks Health Care Medical/Dental Instruments Nasdaq

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

Founded: 1997 Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 23.9M IPO Year: 2008
Target Price: $32.50 AVG Volume (30 days): 22.2K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.82 EPS Growth: 65.79
52 Week Low/High: $0.30 - $7.44 Next Earning Date: 11-12-2026
Revenue: $22,503,908 Revenue Growth: 48.53%
Revenue Growth (this year): 2.14% Revenue Growth (next year): 16.24%
P/E Ratio: -1.38 Index: N/A
Free Cash Flow: -12541000.0 FCF Growth: N/A

AI-Powered CTSO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 2 days ago

AI Recommendation

sell
Model Precision: 0.00%
0.00%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Cytosorbents Corporation (CTSO)

Chan Phillip P.

Chief Executive Officer

Buy
CTSO Sep 4, 2026

Avg Cost/Share

$0.35

Shares

200,000

Total Value

$70,000.00

Owned After

1,944,432

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K/A BUY

Nov 19, 2026 · 98% conf.

AI Prediction BUY

1D

+5.33%

$5.77

Act: -10.52%

5D

+57.17%

$8.61

20D

+58.89%

$8.70

Price: $5.48 Prob +5D: 99% AUC: 1.000
0001104659-26-129936

EX-99.1

2 tm2630146d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves

Operating Cash Flow Breakeven, and Provides Business and

Regulatory Update

Delivering on the First of Four Distinct Value Drivers

PRINCETON,

N.J., November 12, 2026, as updated on November 19, 2026 (see Explanatory Note) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.

Third Quarter 2026 Financial Results

·Revenue was $9.7 million, an increase of 3% compared to $9.5 million in Q3 2025. Growth was led by an 18% increase in distributor and strategic partner sales.

·Gross margin improved to 75% in the quarter, up from 73% in Q2 2026 and 70% a year ago.

·Total operating expenses decreased 11% to $8.5 million from $9.5 million in Q3 2025. Excluding $0.25 million of restructuring charges, operating expenses decreased 13%.

·Operating loss improved by 59% to $1.2 million versus $2.9 million in Q3 2025.

·Net loss improved by 35% to $2.1 million or $0.65 per share, compared to a net loss of $3.2 million or $1.01 per share in Q3 2025. All per share amounts reflect the 1-for-20 reverse stock split effected on September 8, 2026.

·Adjusted net loss, which excludes the impact of non-cash changes in foreign currency transactions, non-cash stock compensation, and restructuring charges, improved by 42% to $1.5 million or $0.48 per share, compared to an adjusted net loss of $2.6 million or $0.83 per share in Q3 2025.

·Adjusted EBITDA loss, which excludes interest payments, depreciation, taxes, and amortization, as well as the impact of non-cash changes in foreign currency transactions, non-cash stock compensation, and restructuring charges, improved by 86% to $0.3 million compared to a loss of $2.0 million in Q3 2025.

·Total cash, cash equivalents, and restricted cash was approximately $5.7 million on September 30, 2026, compared to $5.9 million at June 30, 2026.

·Importantly, the Company generated positive operating cash flow of approximately $43,000 in the quarter, excluding approximately $251,000 in restructuring-related payments, achieving its objective of operating cash flow breakeven in the second half of 2026. Total cash burn in the quarter, inclusive of restructuring-related payments, was approximately $200,000.

Nine Months Ended September 30, 2026 Financial Results

·Revenue was $28.2 million compared to $27.8 million in the first nine months of 2025.

·Gross margin improved to 73% compared to 71% in the prior year period.

·Total operating expenses decreased 9% to $27.4 million, and operating loss improved by 34% to $6.9 million from $10.4 million.

·Net loss was $12.0 million or $3.82 per share, compared to $2.7 million or $0.87 per share in the prior year period, with the change due primarily to a $2.5 million non-cash foreign currency loss in 2026 versus a $9.1 million non-cash foreign currency gain in 2025.

·Adjusted EBITDA loss improved by 45% to $4.0 million compared to a loss of $7.3 million in the prior year period.

“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business. Product gross margin expanded to 75%, operating expenses declined 11%, operating loss improved 59%, and notably, adjusted EBITDA loss narrowed 86% to approximately $0.3 million. These results demonstrate the impact of our more efficient cost structure and position us to benefit from improved operating leverage as revenue grows. Importantly, every dollar of operating cash burn we eliminate helps reduce our future financing needs and positions us to capture more of the potential value of future growth for our shareholders.

Progress on Our Four Distinct Value Drivers

“We continue to advance four distinct value drivers, each with the potential to create meaningful shareholder value. These include achieving sustainable operating cash flow breakeven, restoring profitable growth in our core CytoSorb business, opening the U.S. market through DrugSorb-ATR, and unlocking the strategic value of HemoDefend-BGA. With our first milestone achieved, we are focused on sustaining this progress while advancing the remaining three opportunities.

First Value Driver: Achieving Operating Cash Flow Breakeven — Achieved in Q3 2026

“In the third quarter, we generated approximately $43,000 in positive operating cash flow, excluding $251,000 in restructuring-related payments, compared with operating cash burn of approximately $200,000 in Q2 2026 on the same basis

2026
Q3

Q3 2026 Earnings

8-K BUY

Nov 12, 2026 · 98% conf.

AI Prediction BUY

1D

+5.33%

$5.77

Act: -10.52%

5D

+57.17%

$8.61

20D

+58.89%

$8.70

Price: $5.48 Prob +5D: 99% AUC: 1.000
0000929638-26-004267

EX-99.1

2 exhibit99-1.htm

PRESS RELEASE OF THE COMPANY, DATED NOVEMBER 12, 2026

Exhibit 99.1

CytoSorbents Reports Third Quarter 2026 Financial Results, Achieves Operating Cash Flow Breakeven, and Provides Business and Regulatory Update

Delivering on the First of Four Distinct Value Drivers

PRINCETON, N.J., November 12, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the third quarter ended September 30, 2026, recent business highlights, and provides a regulatory update.

Third Quarter 2026 Financial Results

•

Revenue was $9.7 million, an increase of 3% compared to $9.5 million in Q3 2025. Growth was led by a 16% increase in distributor and strategic partner sales.

•

Gross margin improved to 75% in the quarter, up from 73% in Q2 2026 and 70% a year ago.

•

Total operating expenses decreased 11% to $8.5 million from $9.5 million in Q3 2025. Excluding $0.25 million of restructuring charges, operating expenses decreased 13%.

•

Operating loss improved by 59% to $1.2 million versus $2.9 million in Q3 2025.

•

Net loss improved by 42% to $1.8 million or $0.58 per share, compared to a net loss of $3.2 million or $1.01 per share in Q3 2025. All per share amounts reflect the 1-for-20 reverse stock split effected on September 8, 2026.

•

Adjusted net loss, which excludes the impact of non-cash changes in foreign currency transactions, non-cash stock compensation, and restructuring charges, improved by 42% to $1.5 million or $0.48 per share, compared to an adjusted net loss of $2.6 million or $0.83 per share in Q3 2025.

•

Adjusted EBITDA loss, which excludes interest payments, depreciation, taxes, and amortization, as well as the impact of non-cash changes in foreign currency transactions, non-cash stock compensation, and restructuring charges, improved by 86% to $0.3 million compared to a loss of $2.0 million in Q3 2025.

•

Total cash, cash equivalents, and restricted cash was approximately $5.7 million on September 30, 2026, compared to $5.9 million at June 30, 2026.

•

Importantly, the Company generated positive operating cash flow of approximately $43,000 in the quarter, excluding approximately $251,000 in restructuring-related payments, achieving its objective of operating cash flow breakeven in the second half of 2026. Total cash burn in the quarter, inclusive of restructuring-related payments, was approximately $200,000.

Nine Months Ended September 30, 2026 Financial Results

•

Revenue was $28.2 million compared to $27.8 million in the first nine months of 2025.

•

Gross margin improved to 73% compared to 71% in the prior year period.

•

Total operating expenses decreased 9% to $27.4 million, and operating loss improved by 34% to $6.9 million from $10.4 million.

•

Net loss was $11.4 million or $3.62 per share, compared to $2.7 million or $0.87 per share in the prior year period, with the change due primarily to a $1.9 million non-cash foreign currency loss in 2026 versus a $9.1 million non-cash foreign currency gain in 2025.

•

Adjusted EBITDA loss improved by 45% to $4.0 million compared to a loss of $7.3 million in the prior year period.

“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.  “This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.  Product gross margin expanded to 75%, operating expenses declined 11%, operating loss improved 59%, and notably, adjusted EBITDA loss narrowed 86% to approximately $0.3 million.  These results demonstrate the impact of our more efficient cost structure and position us to benefit from improved operating leverage as revenue grows.  Importantly, every dollar of operating cash burn we eliminate helps reduce our future financing needs and positions us to capture more of the potential value of future growth for our  shareholders.

Progress on Our Four Distinct Value Drivers

“We continue to advance four distinct value drivers, each with the potential to create meaningful shareholder value.  These include achieving sustainable operating cash flow breakeven, restoring profitable growth in our core CytoSorb business, opening the U.S. market through DrugSorb-ATR, and unlocking the strategic value of HemoDefend-BGA.  With our first milestone achieved, we are focused on sustaining this progress while advancing the remaining three opportunities.

First Value Driver: Achieving Operating Cash Flow Breakeven — Achieved in Q3 2026

“In the third quarter, we generated approximately $43,000 in positive operating cash flow, excluding $251,000 in restructuring-related payments, compared with operating cash burn of approximately $200,000 in Q2 2026 on the s

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 99% conf.

AI Prediction BUY

1D

+5.37%

$0.42

Act: -9.68%

5D

+10.16%

$0.44

20D

+12.53%

$0.45

Price: $0.40 Prob +5D: 100% AUC: 1.000
0001104659-26-092039

EX-99.1

2 tm2622246d1_ex99-1.htm

EXHIBIT 99.1

Exhibit 99.1

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Highlighting Four Independent Drivers of Shareholder Value

PRINCETON, N.J.,

August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2026, recent business highlights, and provides a regulatory update.

Second Quarter 2026 Financial Results

·Revenue was $9.6 million, unchanged from a year ago.

·Gross margin improved to 73% in the quarter, up sequentially from 69% in Q1 2026 and from 71% a year ago.

·Operating loss improved by 27% to $2.6 million versus $3.6 million in Q2 2025.

·Net loss was $4.4 million or $0.07 per share, compared to net income of $1.9 million or $0.03 per share in Q2 2025, due primarily to the non-cash impact of changes in foreign currency translations year over year.

·Adjusted net loss, which excludes the impact of non-cash changes in foreign currency translations and non-cash stock compensation, improved by 22% to $2.8 million or $0.05 per share, compared to an adjusted net loss of $3.7 million or $0.06 per share in Q2 2025.

·Adjusted EBITDA loss, which also excludes the impact of non-cash changes in foreign currency translations and non-cash stock compensation improved by 38% to $1.6 million compared to a loss of $2.6 million in Q2 2025.

·Total cash, cash equivalents, and restricted cash was approximately $5.9 million on June 30, 2026, compared to $6.3 million at March 31, 2026.

·Total cash burn in the second quarter was reduced to $0.4 million, inclusive of approximately $0.2 million in restructuring-related payments.

“Second quarter revenue performance was led by strong growth in our distributor and strategic partner territories, as well as direct sales outside of Germany, but offset by a decline in sales in Germany attributed to a smaller, but more focused sales force. We are encouraged by the improved productivity and sales execution of this team and expect to add three to five new sales representatives through early 2027 to restore full country coverage,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “We are also pleased with the continued improvements in our operating execution in the quarter, including an increase in gross margins to 73%, a 27% reduction in operating loss, a 38% improvement in adjusted EBITDA loss, and importantly, a reduction in operating cash burn to $200,000 excluding restructuring payments. These gains reflect disciplined execution across our organization, including manufacturing optimization, improved working capital management, commercial execution, and tighter cost controls. As a result, we believe we remain on track toward our objective of achieving operating cash flow breakeven in the second half of this year.

Over the past couple of years, our priorities have been clear. We have needed to strengthen the financial foundation of the Company, improve commercial and operating execution, advance our regulatory programs, and position the business for sustainable long-term growth. During the second quarter, we continued making meaningful progress against each of these objectives. While we are not yet where we want to be, we believe CytoSorbents today is better positioned for success than it was a year ago.

Four Independent Value Drivers

Looking ahead, we believe CytoSorbents has strong value creation opportunities. We believe we have four independent value drivers over the next six to eighteen months and that each has the potential to strengthen the business and create meaningful long-term shareholder value by reducing risk, expanding profitability, opening new markets, and unlocking strategic value.

First Value Driver: Achieving Operating Cash Flow Breakeven

Our first value driver is reducing financial risk by achieving sustainable operating cash flow breakeven.

Over the past year, we have focused relentlessly on improving the economics of our business. Product gross margin improved to 73% during the second quarter through manufacturing optimization, improved sourcing, and production efficiencies. We also lowered our cash burn through improved commercial execution, collections, and working capital management while continuing to streamline our organization. Since September 2025, we have reduced our workforce by approximately 23%, creating a leaner and more focused company.

As a result, operating cash burn declined to approximately $200,000 during the quarter, excluding restructuring charges, representing another meaningful step toward operating cash flow breakeven.

We believe this milestone is important because it fundamentally changes the Company's financial profile. Every dollar of operating cash burn eliminated reduces future financing needs, strengthen

Share on Social Networks: